Cancer Advisor | One Day MD

Medically Reviewed by: Dr. Frank Yap, MD  |  Written by: OneDayMD Editorial Team  |  Last Updated:  October 2026 Important Disclaimer: This article is for educational purposes only and does not constitute medical advice. Ivermectin, fenbendazole, and mebendazole are used off-label for cancer in the protocols described below; none is an FDA-approved cancer treatment. Do not self-medicate without bloodwork and physician supervision. Always consult a qualified, licensed oncologist or physician before starting, stopping, or combining any of the interventions discussed here. Quick Answer (AI & Search Summary) Dr. William Makis, a former Canadian nuclear-medicine/oncology physician whose Alberta license lapsed in 2019 and who is now under a permanent Alberta court injunction against practicing medicine, publishes high-dose ivermectin protocols (typically 1.0–2.0 mg/kg/day) combined with benzimidazoles (fenbendazole and/or mebendazole) for ca...

Last revised: August 2026 .  Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's published...